Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer

Elicio Reports Complete Responses with ELI-002 7P and Subsequent Checkpoint Inhibition

Elicio Therapeutics reported preliminary clinical observations showing complete radiographic and metabolic responses in three metastatic mKRAS pancreatic cancer patients. These patients had previously progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and subsequently received nivolumab-based therapy. The responses, including two patients maintaining CRs for at least eight months and one for over 13 months, are significant given the historically low complete response rates (0-8%) in this disease, especially in the microsatellite stable (MSS) / mismatch repair proficient (MMR-p) population. Elicio believes these observations suggest ELI-002 7P-induced immune responses may enhance sensitivity to checkpoint inhibition, supporting plans for a Phase 1 study evaluating ELI-002 7P in combination with checkpoint inhibition and standard therapy in first-line metastatic mKRAS PDAC.

• Three patients with metastatic mKRAS pancreatic cancer, who had progressed after ELI-002 7P treatment in the Phase 2 AMPLIFY-7P study, achieved confirmed complete radiographic and metabolic responses following subsequent nivolumab-based therapy. These responses were accompanied by normalization of tumor biomarker CA19-9 levels, with two patients maintaining CRs for at least eight months and one ongoing at over 13 months.
• The observed complete responses are particularly notable as they occurred in microsatellite stable (MSS) / mismatch repair proficient (MMR-p) patients, a population historically demonstrating limited responsiveness to immune checkpoint inhibitors. Published studies in metastatic pancreatic cancer report complete response rates of only 0-8% with existing chemotherapy, checkpoint inhibitor, or RAS inhibitor regimens, making these durable responses exceptionally rare.
• Elicio Therapeutics interprets these observations as preliminary clinical support for the hypothesis that ELI-002 7P-induced mKRAS-specific T cell responses may synergize with checkpoint inhibition to enable deep antitumor responses. This rationale underpins the company's intent to initiate a Phase 1 study evaluating ELI-002 7P in combination with standard gemcitabine/nab-paclitaxel chemotherapy and an anti-PD-1 inhibitor in treatment-naïve metastatic mKRAS PDAC, subject to funding.

Why Complete Responses in mKRAS PDAC Are Rare

Approved systemic therapies for metastatic pancreatic ductal adenocarcinoma (PDAC) have historically delivered modest clinical benefit at best. Gemcitabine, the only cytotoxic agent approved by the FDA for inoperable pancreatic cancer since 1997, remains a cornerstone of treatment, yet yields a median time-to-tumor progression of just 2–3 months and a median overall survival of 4–6 months in the metastatic setting. The addition of erlotinib to gemcitabine represented the only combination to significantly prolong survival in a regulatory sense, though the benefit was clinically marginal — extending median survival by approximately two weeks. While erlotinib-based combination therapy demonstrated a statistically significant improvement in progression-free survival (HR = 0.78, 95% CI: 0.66–0.92, P = 0.003), it conferred no meaningful gain in overall survival (HR = 0.99, 95% CI: 0.72–1.37, P = 0.95) or disease control rate, and was associated with significantly elevated rates of diarrhea and rash. FOLFIRINOX subsequently demonstrated superior overall survival versus gemcitabine monotherapy, though its application remains limited by toxicity, and no consensus exists for second-line treatment.

The near-universal prevalence of oncogenic KRAS mutations in PDAC — estimated at 70–90% across tumor specimens — has been a central driver of therapeutic futility. KRAS hyperactivation confers resistance to multiple drug classes, sustains aggressive tumorigenesis, and promotes rapid metastasis, rendering conventional and EGFR-targeted strategies largely ineffective in this population. Cetuximab, for instance, failed to improve response or survival in phase II and III studies of advanced PDAC. Data from 110 unresectable PDAC patients treated with gemcitabine plus nab-paclitaxel further illustrate the prognostic weight of KRAS status: patients with wild-type KRAS had significantly longer PFS and OS (19.9 and 11.8 months, respectively) compared to those with mutant KRAS (6.9 and 5.3 months, respectively), with wild-type status identified as an independent predictor of both endpoints (PFS: HR = 0.53, P = 0.045; OS: HR = 0.35, P = 0.007).

Targeted inhibition of specific KRAS variants has opened a narrow but important therapeutic window, though its applicability in PDAC remains limited. Sotorasib, a covalent KRAS G12C inhibitor, received conditional approval and marked a significant conceptual advance; however, KRAS G12C accounts for only approximately 2% of KRAS mutations in PDAC, substantially limiting its patient reach. A phase II trial of vemurafenib and sorafenib combination therapy in KRAS-mutated refractory pancreatic cancer reported a disease control rate of 0%, median PFS of 1.6 months, and median OS of 2.9 months — underscoring the resistance mechanisms that persist even with targeted approaches. Acquired resistance to G12C inhibitors, mediated through mutations in PIK3CA and KRAS as well as amplifications of KRAS G12C, MYC, MET, EGFR, and CDK6, further limits durability of response. The vast majority of KRAS-mutant PDAC — driven by G12D, G12V, and other non-G12C variants — remains without an approved targeted therapy, representing a critical unmet need.

Addressing Challenges in Metastatic mKRAS Pancreatic Cancer

Metastatic pancreatic cancer harboring KRAS mutations represents one of oncology's most intractable challenges, with a 5-year survival rate below 10% and a median overall survival of approximately 6 months following diagnosis of metastatic disease. Despite KRAS mutations driving ~90–95% of pancreatic ductal adenocarcinoma (PDAC) cases, no KRAS-targeted therapy had reached clinical approval for this indication as of 2019, reflecting the profound difficulty of translating preclinical promise into meaningful patient benefit.

• Intrinsic resistance of KRAS to direct inhibition: For decades, KRAS was considered undruggable due to its high GTP affinity and lack of accessible allosteric binding pockets. Even as covalent KRAS G12C inhibitors (sotorasib, adagrasib) achieved regulatory approval in NSCLC, their utility in PDAC is severely constrained by the low prevalence of the G12C variant, which occurs in only 2–3% of PDAC cases. The most common mutations — G12D (44%), G12V (34%), and G12R (20%) — remain comparatively underserved by approved agents.

• Limitations of the chemotherapy backbone: Gemcitabine remains the foundational agent across all treatment settings — adjuvant, locally advanced, and metastatic — yet its efficacy is undermined by poor drug distribution to the tumor and rapidly acquired chemoresistance. The addition of erlotinib, the only targeted agent to demonstrate any survival benefit in combination with gemcitabine in a phase III trial, extended median survival by a clinically marginal two weeks.

• Failure of molecularly targeted therapies in the clinical setting: Despite encouraging laboratory data, targeted agents directed at the KRAS vertical signaling pathway — including RAF, MEK, and ERK inhibitors — have demonstrated limited clinical benefit as monotherapies. Broader molecular targeting of key drivers such as KRAS and TGFβ signaling pathways has similarly failed to improve survival outcomes versus nontargeted chemotherapy.

• Emergence of resistance mechanisms to KRAS-directed agents: Even as novel inhibitors such as MRTX1133 (KRAS G12D-directed) enter clinical development, resistance poses a formidable obstacle. Anticipated resistance mechanisms include secondary KRAS mutations, receptor tyrosine kinase reactivation, KRAS-independent bypass signaling, and reactivation of RAS-MAPK signaling — paralleling resistance patterns already observed with G12C inhibitors. Variable efficacy of MRTX1133 has been observed across cell line and organoid models, underscoring heterogeneity in tumor response.

• Immunosuppressive tumor microenvironment and stromal barriers: Immunotherapy as a monotherapy has demonstrated limited effectiveness in PDAC, attributable to a profoundly immunosuppressive tumor microenvironment and dense desmoplastic stroma that restricts drug delivery. While synergistic effects have been noted when immunotherapy is paired with KRAS-targeted agents, robust clinical validation remains pending.

• Absence of consensus in second-line treatment: While gemcitabine-based regimens are broadly accepted as standard first-line therapy for locally advanced or metastatic pancreatic adenocarcinoma, no consensus exists regarding second-line treatment strategies, leaving a critical therapeutic gap for patients who progress on initial therapy.

Elicio's Planned Phase 1 Combination Study Design

Across the available literature, key trials and analyses in metastatic KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) span early-phase interventional studies through large retrospective real-world cohorts, collectively characterizing the prognostic and predictive impact of specific KRAS variant subtypes. The evidence base ranges from a 2011 phase II cetuximab combination trial to 2025–2026 clinicogenomic analyses stratifying outcomes by KRAS allele.

ELI-002 7P: Unlocking Checkpoint Inhibitor Potential in mKRAS PDAC

The recent preliminary clinical observations from Elicio Therapeutics regarding ELI-002 7P in metastatic mKRAS pancreatic cancer (PDAC) present a compelling, albeit early, signal in a notoriously difficult-to-treat disease. The report of complete radiographic and metabolic responses in three patients, who had previously progressed on ELI-002 7P monotherapy and subsequently received nivolumab-based checkpoint inhibition, is particularly noteworthy. Pancreatic cancer, especially the mKRAS subtype, is characterized by extremely low complete response rates, typically ranging from 0-8%, even with advanced therapies. The durability of these responses, extending beyond eight months for two patients and over 13 months for another, suggests a potential for profound clinical benefit in a patient population desperately in need of more effective options.
This development carries significant strategic implications. It suggests a potential repositioning of ELI-002 7P from a standalone therapy to a crucial priming agent that could sensitize 'cold' tumors to existing immunotherapies. If validated, this mechanism could expand the utility of checkpoint inhibitors into patient populations, like those with mKRAS PDAC, where these agents have historically shown limited efficacy. The company's plan for a Phase 1 study evaluating ELI-002 7P in combination with checkpoint inhibition and standard therapy in first-line metastatic mKRAS PDAC underscores confidence in this synergistic approach, potentially paving the way for an accelerated development pathway in a high unmet need area.
However, several critical risks must be acknowledged. The observations are derived from a very small patient cohort, making it imperative to validate these findings in larger, controlled studies. Furthermore, the responses occurred in patients who received checkpoint inhibition after progressing on ELI-002 7P, introducing complexity in definitively attributing the synergy. A prospective combination study is essential to clarify the precise contribution of ELI-002 7P and to rule out confounding factors. While the hypothesis of ELI-002 7P-induced immune responses enhancing checkpoint inhibition is compelling, the exact immunological mechanisms underpinning this synergy require further elucidation to fully understand and optimize the combination strategy. Nevertheless, these early signals offer a glimmer of hope for a patient population desperately in need of more effective treatment strategies, potentially marking a significant step forward in tackling one of oncology's toughest challenges.